Facilitating Access to Non-Statin LDL-C Lowering Therapies

In Facilitating Access to Non-Statin LDL-C Lowering Therapies, our panel delves into the following critical questions:

What is your role in helping patients obtain access to non-statin LDL-C lowering therapies?

Is there a standardization of this in your institution?

What are the benefits and limitations of Medicare part B coverage for non-statin LDL-C lowering therapies?

How about for Medicare part D coverage?

Led by the moderator, the experts discuss how healthcare providers play a critical role in helping patients obtain access to non-statin LDL-C–lowering therapies by assisting with prior authorizations, navigating insurance requirements, and providing education on treatment options. The degree of standardization for this process can vary by institution, with some centers having formal protocols while others rely on individual provider initiative. Medicare Part B coverage generally facilitates access for therapies administered in a clinical setting but may have limitations related to cost-sharing and eligibility criteria. Medicare Part D coverage can support outpatient access but often involves formulary restrictions, prior authorizations, and higher out-of-pocket costs, which may impact adherence and timely therapy initiation.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, Expanding the Role of Pharmacists in Non-Statin LDL-C Therapy Utilization, explores whether non-statin LDL-C–lowering therapies are underutilized and how pharmacists can enhance patient access and appropriate prescribing through education, monitoring, and care coordination. It also considers the need for additional clinical data to better define long-term outcomes, comparative effectiveness, and optimal patient selection for these therapies.